US Patent

US9662340 — Testosterone gel compositions and related methods

Method of Use · Assigned to Upsher Smith Laboratories LLC · Expires 2034-02-11 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects gel compositions containing testosterone for transdermal administration and related methods, excluding certain embodiments with the Hsieh enhancer.

USPTO Abstract

Described are gel compositions containing active pharmaceutical ingredient such as testosterone, solvent, and thickener, the gel compositions being useful for transdermal administration of the active ingredient to a patient, and related methods. Certain embodiments of the gel composition specifically exclude Hsieh enhancer.

Drugs covered by this patent

Androgel (TESTOSTERONE) · Besins Hlthcare

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1531`	—	Androgel
`U-1531`	—	Androgel

Patent Metadata

Patent number: US9662340
Jurisdiction: US
Classification: Method of Use
Expires: 2034-02-11
Drug substance claim: No
Drug product claim: Yes
Assignee: Upsher Smith Laboratories LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.